Skip to content
Screener

Dyne Therapeutics, Inc. DYN Other income, net (Note 6)

Other income, net (Note 6) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$15.04M-140%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
Arrowhead Research logo
Arrowhead ResearchARWR
-$1.61M-467%
Wave Life Sciences logo
Wave Life SciencesWVE
-$275K-235%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$214K+3.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.61M+126%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Interest income8,7577,100
Interest expense(4,202)
Other expense, net(133)(89)
Total other income, net4,4227,011
Net loss$(120,854)$(115,361)
Net loss per share—basic and diluted$(0.73)$(1.05)
Weighted average common shares outstanding, basic and diluted165,036,604109,911,628
Comprehensive loss:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s other income, net (note 6)?
Dyne Therapeutics, Inc. (DYN) reported other income, net (note 6) of $4.42M in Q1 2026.
How has Dyne Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
Dyne Therapeutics, Inc.'s other income, net (note 6) decreased by 36.9% year-over-year, from $7.01M to $4.42M.
What is the long-term trend for Dyne Therapeutics, Inc.'s other income, net (note 6)?
Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s other income, net (note 6) has grown at a 133.9% compound annual growth rate (CAGR), from $734K to $21.97M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Dyne Therapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude